前列腺切除术后前列腺窝立体定向体部放疗的1期试验
这项1期试验评估前列腺切除术后前列腺窝大分割立体定向体部放疗的剂量爬坡,测试3.6 Gy×15次、4.7 Gy×10次和7.1 Gy×5次三个剂量水平,采用6+6规则设计,24例患者入组。结果未观察到≥3级胃肠或泌尿毒性,但各剂量水平均出现一过性2级直肠毒性。作者结论为剂量递增至7.1 Gy×5次可行,需长期随访评估晚期毒性。
要点
- 剂量递增至7.1 Gy×5次至前列腺窝完成,未出现急性≥3级胃肠或泌尿毒性。
- 各剂量水平放疗期间及之后即刻出现一过性2级直肠毒性,多数10周内缓解。
- 作者提出须进行长期随访并评估前列腺窝立体定向体部放疗的晚期毒性。
核心结论
- 剂量递增至7.1 Gy×5次至前列腺窝完成,无急性≥3级胃肠或泌尿毒性。
- 各剂量水平放疗期间及之后即刻出现一过性2级直肠毒性。
- 作者提出须进行长期随访并评估前列腺窝立体定向体部放疗的晚期毒性。
研究设计与样本
- 1期试验,测试前列腺窝大分割剂量递增,剂量水平为3.6 Gy×15次(DL1)、4.7 Gy×10次(DL2)、7.1 Gy×5次(DL3)。
- 采用6+6规则设计进行递增,最大耐受剂量需12例患者。
- 剂量限制毒性定义为美国国家癌症研究所不良事件通用术语标准(版本4.03)≥3级胃肠或泌尿毒性。
- 24例有辅助或挽救放疗指征的患者入组(DL1和DL2各6例,DL3 12例),所有患者随访至少6个月(中位随访14.1个月)。
- 4例患者接受同步雄激素剥夺治疗。
主要发现
- 任何剂量水平均未见≥3级胃肠或泌尿毒性。
- 放疗期间2级胃肠毒性:DL1组6例中2例,DL2组6例中3例,DL3组12例中7例。
- 除1例外,所有急性2级胃肠毒性在10周内缓解。
- 放疗后2周内报告泌尿毒性增至1级和2级:DL1和DL2组12例中3例,DL3组12例中1例。
- 放疗后第2周,26项扩展前列腺癌指数综合肠道领域下降达到最小重要差异标准者占71%;第10周时,DL1、DL2、DL3分别有6例中1例、6例中2例、11例中7例仍符合最小重要差异标准。
局限性
- 作者提出须进行长期随访并评估前列腺窝立体定向体部放疗的晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary objective was to evaluate the maximum tolerated dose (within 10 weeks after treatment) associated with increasing hypofractionation to the prostate fossa (PF). We hypothesized that escalating the dose per fraction (fx) to the PF would have acceptable toxicity. MATERIALS AND METHODS: Tested dose levels (DLs) were 3.6 Gy × 15 fx (DL1); 4.7 Gy × 10 fx (DL2); and 7.1 Gy × 5 fx (DL3). Escalation followed a 6 + 6 rules-based design with 12 patients required at the maximum tolerated dose. Dose-limiting toxicity was defined as grade (G) ≥3, gastrointestinal (GI) or genitourinary (GU) toxicity by National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). Patients completed quality-of-life questionnaires. RESULTS: Twenty-four patients with indications for adjuvant or salvage radiation therapy (RT) enrolled (6 at DL1 and 2; 12 at DL3). All patients had at least 6 months of follow-up (median follow-up, 14.1 months). Four patients received concurrent androgen deprivation therapy. No G ≥ 3 GI or GU toxicity was seen at any DL; 2 of 6 patients in the DL1 group, 3 of 6 in DL2, and 7 of 12 in DL3 experienced G2 GI toxicity during RT. Except in 1 patient, all acute G2 GI toxicity resolved by 10 weeks. Three of 12 patients reported an increase to G1 and G2 GU toxicity in the 2 weeks after RT in groups DL1 and DL2 and 1 of 12 patients in DL3. At week 2 after RT, decline in the 26-item Expanded Prostate Cancer Index Composite bowel domain met criteria for a minimally important difference in 71% of patients. At week 10, 1 of 6, 2 of 6, and 7 of 11 patients at DLs 1, 2, and 3, respectively, still met minimally important difference criteria. International Prostate Symptom Scores worsened 2 weeks after treatment but improved by 6 to 10 weeks. CONCLUSIONS: Dose escalation up to 7.1 Gy × 5 fx to the PF was completed without acute G ≥ 3 toxicity. There was transient G2 rectal toxicity at all DLs during and immediately after RT. We must perform long-term follow-up and assessment of late toxicity of SBRT to the PF.
引用
- Ballas LK, Luo C, Chung E, et al. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30605751. doi:10.1016/j.ijrobp.2018.12.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。